Healthia Limited

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, RHC.AX has a market cap of 8.7B. Regarding current trading prices, HLA.AX is priced at A$1.80, while RHC.AX trades at A$38.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas RHC.AX's P/E ratio is 470.88. In terms of profitability, HLA.AX's ROE is +0.04%, compared to RHC.AX's ROE of +0.01%. Regarding short-term risk, HLA.AX is less volatile compared to RHC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HLA.AX.Check RHC.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, REG.AX has a market cap of 2.6B. Regarding current trading prices, HLA.AX is priced at A$1.80, while REG.AX trades at A$8.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas REG.AX's P/E ratio is 175.60. In terms of profitability, HLA.AX's ROE is +0.04%, compared to REG.AX's ROE of -0.75%. Regarding short-term risk, HLA.AX is less volatile compared to REG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HLA.AX.Check REG.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, SNZ.AX has a market cap of 2.5B. Regarding current trading prices, HLA.AX is priced at A$1.80, while SNZ.AX trades at A$10.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas SNZ.AX's P/E ratio is 7.73. In terms of profitability, HLA.AX's ROE is +0.04%, compared to SNZ.AX's ROE of +0.14%. Regarding short-term risk, HLA.AX is more volatile compared to SNZ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for HLA.AX.Check SNZ.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, EHE.AX has a market cap of 547.7M. Regarding current trading prices, HLA.AX is priced at A$1.80, while EHE.AX trades at A$3.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas EHE.AX's P/E ratio is -23.69. In terms of profitability, HLA.AX's ROE is +0.04%, compared to EHE.AX's ROE of -0.07%. Regarding short-term risk, HLA.AX is less volatile compared to EHE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HLA.AX.Check EHE.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, OCA.AX has a market cap of 478M. Regarding current trading prices, HLA.AX is priced at A$1.80, while OCA.AX trades at A$0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas OCA.AX's P/E ratio is 16.50. In terms of profitability, HLA.AX's ROE is +0.04%, compared to OCA.AX's ROE of +0.03%. Regarding short-term risk, HLA.AX is more volatile compared to OCA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for HLA.AX.Check OCA.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, CAJ.AX has a market cap of 413.1M. Regarding current trading prices, HLA.AX is priced at A$1.80, while CAJ.AX trades at A$0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas CAJ.AX's P/E ratio is -38.50. In terms of profitability, HLA.AX's ROE is +0.04%, compared to CAJ.AX's ROE of -0.12%. Regarding short-term risk, HLA.AX is less volatile compared to CAJ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HLA.AX.Check CAJ.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, PSQ.AX has a market cap of 242.4M. Regarding current trading prices, HLA.AX is priced at A$1.80, while PSQ.AX trades at A$1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas PSQ.AX's P/E ratio is 150.00. In terms of profitability, HLA.AX's ROE is +0.04%, compared to PSQ.AX's ROE of +0.03%. Regarding short-term risk, HLA.AX is more volatile compared to PSQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for HLA.AX.Check PSQ.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, AJJ.AX has a market cap of 14.5M. Regarding current trading prices, HLA.AX is priced at A$1.80, while AJJ.AX trades at A$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas AJJ.AX's P/E ratio is -1.90. In terms of profitability, HLA.AX's ROE is +0.04%, compared to AJJ.AX's ROE of -0.15%. Regarding short-term risk, HLA.AX is more volatile compared to AJJ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for HLA.AX.Check AJJ.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, SLA.AX has a market cap of 13.9M. Regarding current trading prices, HLA.AX is priced at A$1.80, while SLA.AX trades at A$0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas SLA.AX's P/E ratio is -24.00. In terms of profitability, HLA.AX's ROE is +0.04%, compared to SLA.AX's ROE of -0.13%. Regarding short-term risk, HLA.AX is less volatile compared to SLA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HLA.AX.Check SLA.AX's competition here

HLA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLA.AX stands at 173.8M. In comparison, FCG.AX has a market cap of 4M. Regarding current trading prices, HLA.AX is priced at A$1.80, while FCG.AX trades at A$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLA.AX currently has a P/E ratio of 35.90, whereas FCG.AX's P/E ratio is 3.70. In terms of profitability, HLA.AX's ROE is +0.04%, compared to FCG.AX's ROE of +0.31%. Regarding short-term risk, HLA.AX is less volatile compared to FCG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for HLA.AX.Check FCG.AX's competition here